Literature DB >> 35640980

Performance of Cervical Screening a Decade Following HPV Vaccination: The Costa Rica Vaccine Trial.

Shang-Ying Hu1,2, Aimée R Kreimer2, Carolina Porras3, Diego Guillén3, Mario Alfaro3, Teresa M Darragh4, Mark H Stoler5, Luis F Villegas3, Rebecca Ocampo3, Ana Cecilia Rodriguez6, Mark Schiffman2, Sabrina H Tsang2, Douglas R Lowy2,7, John T Schiller7, John Schussler8, Wim Quint9, Mitchell H Gail2, Joshua N Sampson2, Allan Hildesheim2, Rolando Herrero3,10.   

Abstract

BACKGROUND: We investigated the impact of human papillomavirus (HPV) vaccination on the performance of cytology-based and HPV-based screening for detection of cervical precancer among women vaccinated as young adults and reaching screening age.
METHODS: A total of 4632 women aged 25-36 years from the Costa Rica HPV Vaccine Trial were included (2418 HPV-vaccinated as young adults and 2214 unvaccinated). We assessed the performance of cytology- and HPV-based cervical screening modalities in vaccinated and unvaccinated women to detect high-grade cervical precancers diagnosed over 4 years and the absolute risk of cumulative cervical precancers by screening results at entry.
RESULTS: We detected 95 cervical intraepithelial neoplasia grade 3 or worse (52 in unvaccinated and 43 in vaccinated women). HPV16/18/31/33/45 was predominant (69%) among unvaccinated participants, and HPV35/52/58/39/51/56/59/66/68 predominated (65%) among vaccinated participants. Sensitivity and specificity of cervical screening approaches were comparable between women vaccinated as young adults and unvaccinated women. Colposcopy referral rates were lower in the vaccinated group for HPV-based screening modalities, but the positive predictive value was comparable between the 2 groups.
CONCLUSIONS: Among women approaching screening ages, vaccinated as young adults, and with a history of intensive screening, the expected reduction in the positive predictive value of HPV testing, associated with dropping prevalence of HPV-associated lesions, was not observed. This is likely due to the presence of high-grade lesions associated with nonvaccine HPV types, which may be less likely to progress to cancer. Published by Oxford University Press 2022.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 35640980      PMCID: PMC9468298          DOI: 10.1093/jnci/djac107

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   11.816


  43 in total

1.  Discovery and validation of candidate host DNA methylation markers for detection of cervical precancer and cancer.

Authors:  Megan A Clarke; Patricia Luhn; Julia C Gage; Clara Bodelon; S Terence Dunn; Joan Walker; Rosemary Zuna; Stephen Hewitt; J Keith Killian; Liying Yan; Andrew Miller; Mark Schiffman; Nicolas Wentzensen
Journal:  Int J Cancer       Date:  2017-05-26       Impact factor: 7.396

2.  Eight-type human papillomavirus E6/E7 oncoprotein detection as a novel and promising triage strategy for managing HPV-positive women.

Authors:  Remila Rezhake; Shang-Ying Hu; Shuang Zhao; Xiao-Qian Xu; Xue-Lian Zhao; Li Zhang; Yan Wang; Xun Zhang; Qin-Jing Pan; You-Lin Qiao; Fang-Hui Zhao
Journal:  Int J Cancer       Date:  2018-10-26       Impact factor: 7.396

3.  Impact of human papillomavirus vaccination on the clinical meaning of cervical screening results.

Authors:  Philip E Castle; Xianhong Xie; Xiaonan Xue; Nancy E Poitras; Thomas S Lorey; Walter K Kinney; Nicolas Wentzensen; Howard D Strickler; Emily A Burger; Mark Schiffman
Journal:  Prev Med       Date:  2018-10-11       Impact factor: 4.018

4.  Adapting cervical cancer screening for women vaccinated against human papillomavirus infections: The value of stratifying guidelines.

Authors:  Kine Pedersen; Emily A Burger; Mari Nygård; Ivar S Kristiansen; Jane J Kim
Journal:  Eur J Cancer       Date:  2018-01-12       Impact factor: 9.162

5.  Prevention of persistent human papillomavirus infection by an HPV16/18 vaccine: a community-based randomized clinical trial in Guanacaste, Costa Rica.

Authors:  Rolando Herrero; Sholom Wacholder; Ana C Rodríguez; Diane Solomon; Paula González; Aimee R Kreimer; Carolina Porras; John Schussler; Silvia Jiménez; Mark E Sherman; Wim Quint; John T Schiller; Douglas R Lowy; Mark Schiffman; Allan Hildesheim
Journal:  Cancer Discov       Date:  2011-09-09       Impact factor: 39.397

6.  Impact of human papillomavirus vaccination on cervical cytology screening, colposcopy, and treatment.

Authors:  Ana Cecilia Rodríguez; Diane Solomon; Rolando Herrero; Allan Hildesheim; Paula González; Sholom Wacholder; Carolina Porras; Silvia Jiménez; Mark Schiffman
Journal:  Am J Epidemiol       Date:  2013-07-10       Impact factor: 4.897

7.  Impact of HPV vaccination on outcome of cervical cytology screening in Denmark-A register-based cohort study.

Authors:  Lise Holst Thamsborg; George Napolitano; Lise Grupe Larsen; Elsebeth Lynge
Journal:  Int J Cancer       Date:  2018-10-01       Impact factor: 7.396

8.  Prevalence of cervical disease at age 20 after immunisation with bivalent HPV vaccine at age 12-13 in Scotland: retrospective population study.

Authors:  Tim Palmer; Lynn Wallace; Kevin G Pollock; Kate Cuschieri; Chris Robertson; Kim Kavanagh; Margaret Cruickshank
Journal:  BMJ       Date:  2019-04-03

9.  Evaluation of TypeSeq, a Novel High-Throughput, Low-Cost, Next-Generation Sequencing-Based Assay for Detection of 51 Human Papillomavirus Genotypes.

Authors:  Sarah Wagner; David Roberson; Joseph Boland; Aimée R Kreimer; Meredith Yeager; Michael Cullen; Lisa Mirabello; S Terence Dunn; Joan Walker; Rosemary Zuna; Carolina Porras; Bernal Cortes; Joshua Sampson; Rolando Herrero; Ana Cecilia Rodriguez; Wim Quint; Leen-Jan Van Doorn; Allan Hildesheim; Mark Schiffman; Nicolas Wentzensen
Journal:  J Infect Dis       Date:  2019-10-08       Impact factor: 5.226

10.  HPV immunisation and cervical screening--confirmation of changed performance of cytology as a screening test in immunised women: a retrospective population-based cohort study.

Authors:  T J Palmer; M McFadden; K G J Pollock; K Kavanagh; K Cuschieri; M Cruickshank; S Cotton; S Nicoll; C Robertson
Journal:  Br J Cancer       Date:  2016-02-04       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.